Article Text

Download PDFPDF
Huntington’s disease: diagnosis and management
  1. Thomas B Stoker1,
  2. Sarah L Mason1,
  3. Julia C Greenland1,
  4. Simon T Holden2,
  5. Helen Santini3,
  6. Roger A Barker1,4
  1. 1 John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
  2. 2 Department of Clinical Genetics, Addenbrooke’s Hospital, Cambridge, UK
  3. 3 Huntington Disease Association, Liverpool, UK
  4. 4 Wellcome Trust Medical Research Council - Cambridge Stem Cell Institute, Cambridge, UK
  1. Correspondence to Dr Thomas B Stoker, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 1TN, UK; tbs26{at}


Huntington’s disease (HD) is an inherited neurodegenerative disease characterised by neuropsychiatric symptoms, a movement disorder (most commonly choreiform) and progressive cognitive impairment. The diagnosis is usually confirmed through identification of an increased CAG repeat length in the huntingtin gene in a patient with clinical features of the condition. Though diagnosis is usually straightforward, unusual presentations can occur, and it can be difficult to know when someone has transitioned from being an asymptomatic carrier into the disease state. This has become increasingly important recently, with several putative disease-modifying therapies entering trials. A growing number of conditions can mimic HD, including rare genetic causes, which must be considered in the event of a negative HD genetic test. Patients are best managed in specialist multidisciplinary clinics, including when considering genetic testing. Current treatments are symptomatic, and largely directed at the chorea and neurobehavioural problems, although supporting trial evidence for these is often limited.

  • genetics
  • huntington-s
  • movement disorders

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors TBS wrote the first draft of the review. SLM, JCG, STH, HS and RAB reviewed and revised the manuscript.

  • Funding The authors acknowledge financial support from the following organisations: Huntington’s Disease Association, National Institute for Health Research (NF-SI-0616-10011), NIHR Cambridge Biomedical Research Centre (BRC-1215-20014).

  • Competing interests None declared.

  • Provenance and peer review Commissioned. Externally peer reviewed by Anne Rosser, Cardiff, UK.

Other content recommended for you